These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Characterization of Second Primary Malignancies in Mucosa-Associated Lymphoid Tissue Lymphomas: A SEER Database Interrogation. Timilsina S; Damato A; Budhathoki N; Grossbard ML; Braunstein M Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):76-81. PubMed ID: 34493476 [TBL] [Abstract][Full Text] [Related]
23. Langerhans cell histiocytosis arising after Hodgkin's disease. Ferrari A; Fabietti P; Vessecchia G; Laffranchi A; Lombardi L; Massimino M; Fossati-Bellani F; Giardini R Pediatr Hematol Oncol; 1997; 14(6):585-8. PubMed ID: 9383812 [TBL] [Abstract][Full Text] [Related]
24. Risk and outcome of second primary malignancy in patients with classical Hodgkin lymphoma. Wang F Medicine (Baltimore); 2022 Dec; 101(48):e31967. PubMed ID: 36482535 [TBL] [Abstract][Full Text] [Related]
25. The Risk of Second Primary Malignancies in Patients With Lung Neuroendocrine Tumors: A Population-Based Study on SEER Database. Bu X; Wang X; Wei L; Liu J; Chen M Curr Probl Cancer; 2020 Dec; 44(6):100613. PubMed ID: 32563531 [TBL] [Abstract][Full Text] [Related]
26. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000-2004. Guyot-Goubin A; Donadieu J; Barkaoui M; Bellec S; Thomas C; Clavel J Pediatr Blood Cancer; 2008 Jul; 51(1):71-5. PubMed ID: 18260117 [TBL] [Abstract][Full Text] [Related]
27. Langerhans cell histiocytosis. Grana N Cancer Control; 2014 Oct; 21(4):328-34. PubMed ID: 25310214 [TBL] [Abstract][Full Text] [Related]
28. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions. Minkov M Paediatr Drugs; 2011 Apr; 13(2):75-86. PubMed ID: 21351807 [TBL] [Abstract][Full Text] [Related]
29. Ethnicity, race, and socioeconomic status influence incidence of Langerhans cell histiocytosis. Ribeiro KB; Degar B; Antoneli CB; Rollins B; Rodriguez-Galindo C Pediatr Blood Cancer; 2015 Jun; 62(6):982-7. PubMed ID: 25586293 [TBL] [Abstract][Full Text] [Related]
30. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020. Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688 [TBL] [Abstract][Full Text] [Related]
31. Additive Prognostic Impact of Gastrointestinal Involvement in Severe Multisystem Langerhans Cell Histiocytosis. Minkov M; Pötschger U; Thacker N; Astigarraga I; Braier J; Donadieu J; Henter JI; Lehrnbecher T; Rodriguez-Galindo C; Sieni E; Nanduri V; van den Bos C; Abla O; J Pediatr; 2021 Oct; 237():65-70.e3. PubMed ID: 34146548 [TBL] [Abstract][Full Text] [Related]
32. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540 [TBL] [Abstract][Full Text] [Related]
36. A multicenter study of patients with multisystem Langerhans cell histiocytosis who develop secondary hemophagocytic lymphohistiocytosis. Chellapandian D; Hines MR; Zhang R; Jeng M; van den Bos C; Santa-María López V; Lehmberg K; Sieni E; Wang Y; Nakano T; Williams JA; Fustino NJ; Astigarraga I; Dunkel IJ; Abla O; van Halteren AGS; Pei D; Cheng C; Weitzman S; Sung L; Nichols KE Cancer; 2019 Mar; 125(6):963-971. PubMed ID: 30521100 [TBL] [Abstract][Full Text] [Related]
37. [Pathophysiology and treatment of adult Langerhans cell histiocytosis]. Tojo A; Kobayashi M Rinsho Ketsueki; 2020; 61(9):1028-1034. PubMed ID: 33162496 [TBL] [Abstract][Full Text] [Related]
38. Langerhans cell histiocytosis of spine: a comparative study of clinical, imaging features, and diagnosis in children, adolescents, and adults. Huang WD; Yang XH; Wu ZP; Huang Q; Xiao JR; Yang MS; Zhou ZH; Yan WJ; Song DW; Liu TL; Jia NY Spine J; 2013 Sep; 13(9):1108-17. PubMed ID: 23602327 [TBL] [Abstract][Full Text] [Related]
39. Mutual Risks of Cutaneous Melanoma and Specific Lymphoid Neoplasms: Second Cancer Occurrence and Survival. Herr MM; Schonfeld SJ; Dores GM; Withrow DR; Tucker MA; Curtis RE; Morton LM J Natl Cancer Inst; 2018 Nov; 110(11):1248-1258. PubMed ID: 29659938 [TBL] [Abstract][Full Text] [Related]
40. Histologic patterns of thymic involvement in Langerhans cell proliferations: a clinicopathologic study and review of the literature. Picarsic J; Egeler RM; Chikwava K; Patterson K; Jaffe R Pediatr Dev Pathol; 2015; 18(2):127-38. PubMed ID: 25629953 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]